ArticleFrontiers in psychiatry2025
Emotional speech markers of psychiatric disturbance in Huntington's disease.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psychiatric disorders and difficulties in emotional expression represent a major problem in the management of Huntington's Disease (HD). To improve patient follow-up, we propose to investigate the link between emotional expression and psychiatric symptoms, measured by the Problem Behaviors Assessment (PBA) scale. To this aim we developed the first emotional/psychiatric speech corpus, emoHD. Methods: We included 102 HD gene carriers and 35 healthy controls (HC). Psychiatric symptoms were assessed using PBA sub-scales for Depression, Irritability/aggressivity, Apathy, and Obsessive/compulsive symptoms. Speech was annotated using three emotional descriptors: primary emotions, affective phenomena, and activation levels. Affective phenomena labels were selected based on PBA statements by external participants unaware of the study's aims. We analyzed (1) emotional descriptors' relationships, (2) emotional expression differences between HD and HC, and (3) the associations between emotions and psychiatric symptoms. Results: HD patients showed reduced emotional expressiveness than HC with more neutral activation levels (=0). Only the primary emotion "angry" was less expressed in HD compared to HC. In contrast they expressed more affective phenomena states like apathetic, confused, "depressed", "disoriented", "frustrated", and "pessimistic" than HC, whereas they expressed less "other" and "irritable" than HC. Expressed emotions were congruent with psychiatric symptoms (e.g., "anxious" and "nervous" are positively associated with Depression PBA sub-scale; "frustrated" with Irritability/aggressivity PBA sub-scale). Conclusion: We showed that speech is a promising marker for emotional/psychiatric symptoms in HD, supporting future remote monitoring and personalized care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.